课题基金 / 基金详情

Accelerating and expanding the therapeutic potential of ERAP1 inhibition in cancer

Accelerating and expanding the therapeutic potential of ERAP1 inhibition in cancer
加速和扩大 ERAP1 抑制在癌症中的治疗潜力
批准号:
92627
负责人:
金额:
$110.58万
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
灰狼治疗公司正在开发下一代癌症免疫治疗方法,这种方法比现有的治疗方法更有效,可以应用于更广泛的癌症。免疫疗法的突破在某些癌症的治疗中具有开创性,对一些晚期患者有很大好处,在某些情况下延长和改善患者的生命多年。然而,大多数类型的癌症都不能被这些疗法所控制,因此,随着癌症发病率的持续增长,开发新药的需求仍然很大。最近的研究表明,肿瘤对免疫系统的可见性是决定它是否会进展和生长的最重要因素之一。肿瘤在细胞表面显示出大量的“非自身”成分,称为新抗原,对当前的免疫疗法特别敏感,因为它们更明显,更有可能被免疫系统识别为“外来”。然而,大多数癌症表面的新抗原数量很少,因此免疫疗法在这些情况下不是很有效。免疫系统根本无法识别这些细胞应该被清除。癌症治疗的未来需要能够解决肿瘤可见性问题的新药。灰狼公司开发了一种创新药物,可以显著改变癌细胞表面的新抗原,将它们照射给免疫系统,现在免疫系统能够识别出应该摧毁这些细胞。这种全新的作用模式在各种癌症类型中都很活跃,因此有可能为成千上万目前没有有效治疗方案的癌症患者提供巨大的益处。
英文摘要
Grey Wolf Therapeutics is developing a next-generation approach to cancer immunotherapy that is more effective than existing treatments and can be applied to a much wider variety of cancers.Breakthroughs in immunotherapy have been ground-breaking in the treatment of some cancers, with great benefits in some patients with advanced disease, in some cases extending and improving the life of patients by many years. However, most types of cancer are not controlled by these therapies, and therefore there remains a huge need to develop new medicines as cancer rates continue to grow. Recent research has shown that the visibility of a tumour to the immune system is one of the most important factors that decides whether it will progress and grow.Tumours that show a high number of 'non-self' components at the cell surface called neoantigens are particularly sensitive to current immunotherapies because they are more visible and likely to be recognized by the immune system as 'foreign'. However, most cancers have low numbers of neoantigens on their surface and therefore immunotherapies are not very effective in these cases. The immune system simply doesn't recognise that the cells should be eliminated. The future of cancer therapy requires new medicines that can address the tumour visibility problem.Grey Wolf has developed an innovate medicine that significantly alters the neoantigens presented on the cancer cell surface, illuminating them to the immune system, which is now able to recognise that the cells should be destroyed. This completely novel mode of action is active across the spectrum of cancer types and as such has the potential to provide huge benefits to thousands of cancer patients who currently have no effective treatment options available to them.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金